Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 431 to 440 of 1520 total matches.

Monoclate: A Purified Antihemophilic Factor

   
The Medical Letter on Drugs and Therapeutics • Jan 01, 1988  (Issue 756)
that it is active in promoting coagulation. The Medical Letter, Vol. 30 (Issue 756) January 1, 1988, pp. 1-2 ...
Monoclate (Armour), a formulation of Factor VIII (antihemophilic factor; AHF) prepared by immunoaffinity chromatography, was recently approved for marketing by the US Food and Drug Administration. The new product is claimed to be more highly purified than older AHF formulations. Factor VIII concentrates commercially available in the USA are listed in the table below.
Med Lett Drugs Ther. 1988 Jan 1;30(756):1-2 |  Show IntroductionHide Introduction

New Copper IUD

   
The Medical Letter on Drugs and Therapeutics • Feb 26, 1988  (Issue 760)
). The Medical Letter, Vol. 30 (Issue 760) February 26, 1988, pp. 25-26 Copyright  The Medical Letter ...
The copper T 380A (ParaGard - GynoPharma), a new intrauterine contraceptive device (IUD) soon to be marketed in the USA, will be one of only two IUDs available in this country. Progestasert (Alza), which gradually releases progesterone (Medical Letter, 18:65, 1976), is the other.
Med Lett Drugs Ther. 1988 Feb 26;30(760):25-6 |  Show IntroductionHide Introduction

Naftifine For Fungal Skin Infections

   
The Medical Letter on Drugs and Therapeutics • Oct 21, 1988  (Issue 777)
, Mykosen, 30 suppl 1:92, 1987). The Medical Letter, Vol. 30 (Issue 777) October 21, 1988 pp. 98-99 ...
Naftifine hydrochloride 1% cream (Naftin - Herbert Laboratories), was recently approved by the US Food and Drug Administration (FDA) for topical treatment of tinea cruris and tinea corporis. It is available only by prescription.
Med Lett Drugs Ther. 1988 Oct 21;30(777):98-9 |  Show IntroductionHide Introduction

Nimodipine for Cerebral Vasospasm Subarachnoid Hemorrhage

   
The Medical Letter on Drugs and Therapeutics • May 19, 1989  (Issue 792)
et al, Neurosurgery, 22:484, 1988). The Medical Letter, Vol. 31 (Issue 792) May 19, 1989, pp. 47-48 ...
Cerebral arterial spasm frequently causes ischemic neurological damage after subarachnoid hemorrhage from a ruptured intracranial aneurysm. Nimodipine (Nimotop - Miles), a 1,4-dihydropyridine calcium-entry blocker, was recently approved by the US Food and Drug Administration (FDA) for oral treatment of such patients; an intravenous preparation is available only for investigational use.
Med Lett Drugs Ther. 1989 May 19;31(792):47-8 |  Show IntroductionHide Introduction

Pentamidine Aerosol To Prevent Pneumocystis Carinii Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Oct 06, 1989  (Issue 802)
. The Medical Letter, Vol. 31 (Issue 802) October 6, 1989, pp. 91-92 Copyright  The Medical Letter ...
Pneumocystis carinii pneumonia (PCP) occurs in nearly 80% of patients with the acquired immune deficiency syndrome (AIDS) and is a common cause of morbidity and mortality. Oral trimethoprim-sulfamethoxazole (Bactrim; and others), intravenous isethionate (Pentam 300) and other systemic drugs have been used to prevent PCP, but in AIDS patients, all of these agents can occasionally cause severe adverse effects (Medical Letter, 30:94, 1988). Recently, the US Food and Drug Administration approved marketing of aerosolized pentamidine isethionate (NebuPent - LyphoMed) for this indication. Another...
Med Lett Drugs Ther. 1989 Oct 6;31(802):91-2 |  Show IntroductionHide Introduction

Bupropion For Depression

   
The Medical Letter on Drugs and Therapeutics • Nov 03, 1989  (Issue 804)
. Agitation has been the most frequent reason for stopping the drug. Dry mouth, headThe Medical Letter, Vol ...
Bupropion (Wellbutrin - Burroughs Wellcome) was recently marketed in the USA for treatment of depression. First approved by the Food and Drug Administration in late 1985, the drug was withdrawn from the market in early 1986 because of a high incidence of seizures in one study.
Med Lett Drugs Ther. 1989 Nov 3;31(804):97-8 |  Show IntroductionHide Introduction

Clozapine for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Jan 12, 1990  (Issue 809)
, Vol. 32 (Issue 809) January 12, 1990, pp. 3-4 Copyright  The Medical Letter UNAUTHORIZED FORWARDING ...
Clozapine (Clozaril - Sandoz), a dibenzodiazepine antipsychotic drug that has been available in Europe for many years, was recently approved for marketing by the US Food and Drug Administration. Because of its toxicity, the labeling for clozapine recommends using the drug only for schizophrenic patients who have not responded adequately to standard antipsychotic drugs or have had intolerable adverse effects.
Med Lett Drugs Ther. 1990 Jan 12;32(809):3-4 |  Show IntroductionHide Introduction

Treatment of Heat Injury

   
The Medical Letter on Drugs and Therapeutics • Jul 13, 1990  (Issue 822)
(CPK) concentrations due to rhabdomyolysis is common The Medical Letter, Vol. 32 (Issue 822) July 13 ...
Summer heat waves cause thousands of cases of heat-related illness in the USA each year and hundreds of heat-related deaths, especially among the elderly. A few principles may be helpful in preventing and treating heat injury.
Med Lett Drugs Ther. 1990 Jul 13;32(822):66-8 |  Show IntroductionHide Introduction

Nafarelin For Endometriosis

   
The Medical Letter on Drugs and Therapeutics • Aug 24, 1990  (Issue 825)
of the three groups (MR Henzl et al, N The Medical Letter, Vol. 32 (Issue 825) August 24, 1990, pp. 81-82 ...
Nafarelin acetate (Synarel - Syntex), a synthetic analog of gonadotropin-releasing hormone (GnRH), was recently approved by the US Food and Drug Administration for treatment of endometriosis. The drug is available only in a nasal spray formulation.
Med Lett Drugs Ther. 1990 Aug 24;32(825):81-2 |  Show IntroductionHide Introduction

Moricizine for Cardiac Arrhythmias

   
The Medical Letter on Drugs and Therapeutics • Nov 02, 1990  (Issue 830)
with asymptomatic or mildly symptomatic ventricular arrhythmias taking the class IC The Medical Letter, Vol. 32 ...
Moricizine (mor i'; siz een) hydrochloride (Ethmozine - Du Pont), a class I antiarrhythmic drug developed in the USSR, was recently approved by the US Food and Drug Administration (FDA) for oral treatment of life-threatening ventricular arrhythmias.
Med Lett Drugs Ther. 1990 Nov 2;32(830):99-100 |  Show IntroductionHide Introduction